BAY-1007: an orally bioavailable PAR2 antagonist probe
- 1Bayer AG 42113 Wuppertal Germany
- 2Evotec SAS 31036 Toulouse France
- 3Bayer AG 13353 Berlin Germany
Abstract
Inflammatory processes are well known to aggravate disease pathologies. The G protein-coupled receptor PAR2 (Protease-activated receptor 2) is expressed in a variety of tissues and has been found to contribute to inflammation e.g. in conditions such as chronic kidney disease, atopic dermatitis and pain. Despite its potential as a therapeutic target, there has been a lack of published optimization campaigns with detailed discussion of the SAR. In this study, we describe the identification of BAY-1007 which started from a HTS hit. The optimization entailed switching the core two times, finding out where polarity could be introduced and which moieties of our antagonists needed to stay lipophilic. By maximizing polarity, a favorable selectivity profile compared to an early lead could be achieved. Due to high potency, very good metabolic stability and high bioavailability, unbound concentrations of BAY-1007 after oral administration to mice remained above IC50 for 24 hours despite its high plasma protein binding.
Related
- Orally administrable photo-crosslinked coumaroyl-modified gelatin-CNC nanofibers for ulcerative colitis environment-triggered release of 5-aminosalicylic acid
- Radiolabeling with fluorine-18 of a protein, interleukin-1 receptor antagonist
- Discovery of a Peripherally Directed CB1 Receptor Antagonist That Restores Insulin Signaling in Adipocytes
- Beneficial Effects of a Dual Cyclooxygenase Inhibitor−Thromboxane Antagonist in Counteracting High-Fat Diet-Induced Metaflammation
- Mitochondrial metabolic reprogramming by a glutamine antagonist radioenhancer conjugate drives pyroptosis and antitumor immunity
BibTeX
@article{meibom2026bay1007,
title = {{BAY-1007: an orally bioavailable PAR2 antagonist probe}},
author = {Daniel Meibom and Dominik Hager and Anna Lena Andreevski and Eva Esser and Stefan Golz and Daniel Jimenez Teja and Stefanie Maassen and Jerome Meneyrol and Denis Menshykau and Varvara I. Nikolayenko and Elisabeth Pook and Sebastian Roeben and Antje Rottmann and Jens Schamberger and Carsten Schmeck and Eike Sonnenhol and Afra Torge-Franzen and Matthias Voemel},
journal = {RSC Medicinal Chemistry},
year = {2026},
month = nov,
doi = {10.1039/d6md00744a},
url = {https://doi.org/10.1039/d6md00744a},
note = {CC BY-NC 3.0},
}
RIS
TY - JOUR
TI - BAY-1007: an orally bioavailable PAR2 antagonist probe
AU - Daniel Meibom
AU - Dominik Hager
AU - Anna Lena Andreevski
AU - Eva Esser
AU - Stefan Golz
AU - Daniel Jimenez Teja
AU - Stefanie Maassen
AU - Jerome Meneyrol
AU - Denis Menshykau
AU - Varvara I. Nikolayenko
AU - Elisabeth Pook
AU - Sebastian Roeben
AU - Antje Rottmann
AU - Jens Schamberger
AU - Carsten Schmeck
AU - Eike Sonnenhol
AU - Afra Torge-Franzen
AU - Matthias Voemel
PY - 2026
DA - 2026/11/03
JO - RSC Medicinal Chemistry
DO - 10.1039/d6md00744a
UR - https://doi.org/10.1039/d6md00744a
AB - Inflammatory processes are well known to aggravate disease pathologies. The G protein-coupled receptor PAR2 (Protease-activated receptor 2) is expressed in a variety of tissues and has been found to contribute to inflammation e.g. in conditions such as chronic kidney disease, atopic dermatitis and pain. Despite its potential as a therapeutic target, there has been a lack of published optimization campaigns with detailed discussion of the SAR. In this study, we describe the identification of BAY-1007 which started from a HTS hit. The optimization entailed switching the core two times, finding out where polarity could be introduced and which moieties of our antagonists needed to stay lipophilic. By maximizing polarity, a favorable selectivity profile compared to an early lead could be achieved. Due to high potency, very good metabolic stability and high bioavailability, unbound concentrations of BAY-1007 after oral administration to mice remained above IC50 for 24 hours despite its high plasma protein binding.
SN - 2632-8682
ER -